China reportedly urged domestic companies to avoid using Nvidia (NVDA) H20 processors, especially for government work, after ...

The research, done in mice and in human cells, shows that a protein called STUB1 restrains the immune system’s elite ...

Novartis drew heightened retail chatter on Monday amid reports that Swiss ministers plan to meet this week with top ...

Currently exempt from US tariffs, pharmaceutical manufacturers fear steep surcharges, as promised by the US president on ...

The Swiss government is due to meet this week with pharmaceuticals firms that U.S. President Donald Trump has asked to lower ...

President Trump on Monday signed an executive order extending the tariff truce between the US and China for another 90 days, reports said, pushing trade negotiations out to the fall. Also, Nvidia ...

Roche (RHHBY) and Novartis (NVS) are scheduled to meet with Swiss officials this week amid U.S. tariff threats on pharma ...

The Swiss government is engaging with pharma companies Roche and Novartis to address U.S. President Trump's demand for price cuts and to negotiate a 39% tariff on Swiss exports. The discussion follows ...

UNITED STATES consumers probably experienced a slight pickup in underlying inflation in July as retailers gradually raised prices on a variety of items subject to higher import duties. The core ...

The chronic lymphocytic leukemia therapeutics market is expected to grow at a compound annual growth rate of 7% from 2025 to ...

Good news in research for Novartis. The pharmaceutical giant has achieved the hoped-for results for Ianalumab, a candidate for the treatment of Sjögren’s Syndrome, a serious autoimmune disease.

Novartis AG said an experimental medicine helped patients with an autoimmune disease in late-stage studies, offering a boost for the Swiss drugmaker’s efforts in the field.